drugset / Trial / NCT02446444
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Phase 3
Active not recruiting
802 enrolled
University of Sydney
Australian and New Zealand Urogenital and Prostate Cancer Trials Group · collabCancer Trials Ireland · collabEuropean Organisation for Research and Treatment of Cancer - EORTC · collabNational Health and Medical Research Council, Australia · collabTrans Tasman Radiation Oncology Group · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at high risk of recurrence.
Timeline
- Start
- 2014-03
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |